San Giovanni Battista University Hospital

At San Giovanni Battista University Hospital in Turin, clinical research in immune system diseases includes studies focused on delayed graft function after kidney transplantation. These trials are designed to assess whether new treatments can improve allograft function and support recovery in transplant recipients at risk of early complications.

• Improving kidney transplant outcomes in patients at risk of delayed graft function
• Evaluating a new therapy aimed at strengthening early graft performance
• Advancing care for deceased donor kidney transplant recipients

This area reflects a strong interest in better post-transplant support and in testing approaches that may help protect transplanted kidneys during the critical recovery period.

Another key research focus is neoplasms, especially myelofibrosis, a serious blood cancer that can be difficult to control after standard treatment. The trials here are evaluating whether new options can improve overall survival and offer better disease control for people whose illness has stopped responding to JAK-inhibitor therapy.

• Studying treatment options for intermediate-2 and high-risk myelofibrosis
• Comparing a new therapy with current available treatments
• Seeking better outcomes for patients with relapsed or refractory disease

This work supports the search for more effective approaches in advanced blood cancers, where treatment choices are often limited and long-term disease control remains a major need.

The site also conducts studies in non-muscle invasive bladder cancer, with attention to patients who have not responded well to BCG therapy or who have high-risk disease. These trials are exploring whether a new intravesical treatment can improve response rates and provide a more effective option for bladder cancer management.

• Testing a new bladder-directed therapy for BCG-unresponsive disease
• Assessing treatment effectiveness in high-risk non-muscle invasive bladder cancer
• Exploring options for patients with incomplete or no prior BCG treatment

This urology research combines cancer care with a practical focus on treatment response, safety, and improved disease control for patients facing difficult-to-treat bladder cancer.